Towards Circulating-Tumor DNA-Based Precision Medicine

Journal of Clinical Medicine

Akihiko Suto¹  Shin Takayama¹  Takahiro Ochiya²  Ai Hironaka-Mitsuhashi²  Anna Sanchez Calle² 

[1] Department of Breast Surgery, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan;Division of Molecular and Cellular Medicine, National Cancer Centre Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan;

关键词: biomarker;    breast cancer;    circulating-tumor DNA;    colorectal cancer;    lung cancer;    precision medicine;    targeted therapy;   

DOI  :  10.3390/jcm8091365

来源: DOAJ

【 摘 要 】

In the era of precision medicine, targeted therapies have been implemented for various diseases. Genomic information guides decision-making in cancer treatment. The improvements in next-generation sequencing and polymerase chain reaction have made it possible to access the genetic information using circulating-tumor DNAs (ctDNAs). Molecular characteristics of individual tumors can be obtained by analysis of ctDNAs, thus making them excellent tools to guide decision-making during treatment. In oncology, the use of ctDNAs in clinical practice is now gaining importance. Molecular analysis of ctDNAs has potential for multiple clinical applications, including early diagnosis, prognosis of disease, prognostic and/or predictive biomarkers, and monitoring response to therapy and clonal evolution. In this paper, we highlight the applications of ctDNAs in cancer management, especially in metastatic setting, and summarize recent studies about the use of ctDNAs as predictive biomarkers for the therapeutic adaptation/response in lung cancer, breast cancer, and colorectal cancer. These studies offer the evidence to use ctDNAs as a promising approach to solve unmet clinical needs.

【 授权许可】

Unknown